scholarly journals A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer

1992 ◽  
Vol 66 (2) ◽  
pp. 402-404 ◽  
Author(s):  
AR Dixon ◽  
L Jackson ◽  
S Chan ◽  
J Haybittle ◽  
RW Blamey
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Randomised Trial ◽  
Advanced Breast ◽  
Second Line ◽  
Tamoxifen Resistant ◽  
Single Agent Chemotherapy

scholarly journals Sequential dose-dense single agent chemotherapy for locally advanced breast cancer

2003 ◽  
Vol 11 (3) ◽  
pp. 149-149
Author(s):  
Svetislav Vrbic ◽  
Ivica Pejcic ◽  
Sladjana Filipovic ◽  
Stojan Radic
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Single Agent ◽  
Locally Advanced ◽  
Conservative Surgery ◽  
Advanced Breast ◽  
Dose Dense ◽  
Novel Concept ◽  
Single Agent Chemotherapy

Chemotherapy of breast cancer is still the area of intensive research. Based on mathematical model of tumor cell growth kinetics, articulated by Larry Norton, novel concept of chemotherapy in breast cancer was launched and it implies dose-densification of chemotherapy trough the use of sequential non cross-resistant single agents or regimens. The introduction of primary systemic chemotherapy (PST) improved the outcome of patients with locally advanced breast cancer (LABC). Simultaneous PST is the standard approach to patients with LABC nowadays. On the other hand, many studies using two most active cytotoxic drugs in primary breast cancer, anthracyclines and taxanes showed that sequential dose-dense single agent PST could be superior in terms of enhancing the rates of patients suitable for conservative surgery. In the light of this data, based on the results of the new clinical trials we will discuss merits and demerits of using sequential dose-dense single agent chemotherapy in LABC.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

1995 ◽  
Vol 13 (11) ◽  
pp. 2722-2730 ◽  
Author(s):  
B L Weber ◽  
C Vogel ◽  
S Jones ◽  
H Harvey ◽  
L Hutchins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Objective Response ◽  
Advanced Breast ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Second Line Therapy ◽  
Line Therapy

PURPOSE We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. PATIENTS AND METHODS A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. RESULTS The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second-line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. CONCLUSION Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

scholarly journals Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life

1993 ◽  
Vol 67 (2) ◽  
pp. 402-406 ◽  
Author(s):  
SCA Fraser ◽  
HJ Dobbs ◽  
SR Ebbs ◽  
LJ Fallowfield ◽  
T Bates ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Advanced Breast ◽  
Single Agent Chemotherapy

An open randomised trial of second-line endocrine therapy in advanced breast cancer

2003 ◽  
Vol 39 (16) ◽  
pp. 2318-2327 ◽  
Author(s):  
C. Rose ◽  
O. Vtoraya ◽  
A. Pluzanska ◽  
N. Davidson ◽  
M. Gershanovich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Randomised Trial ◽  
Advanced Breast ◽  
Second Line

scholarly journals Cost of Adverse Events During Treatment with Everolimus Plus Exemestane or Single-Agent Chemotherapy in Patients with Advanced Breast Cancer

2013 ◽  
Vol 16 (7) ◽  
pp. A401-A402
Author(s):  
M. Campone ◽  
H. Yang ◽  
E. Faust ◽  
A. Kageleiry ◽  
J. Signorovitch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Advanced Breast ◽  
Single Agent Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document